EN DE
Watch SK Bioscience Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

SK Bioscience Co Ltd (302440) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of SK Bioscience Co Ltd stock KRW 33,575, price KRW 39,700, that is 15.4% below the price, quality 45 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7302440003

SB SK Bioscience Co Ltd logo Thin data Nov 11, 2026

SK Bioscience Co Ltd

302440 · KO
Expensive, weak quality

Our calculation puts a fair price 15% below what the stock costs today.

Low debt
Ranks above peers (6/10)
Quality 45/100
Expensive Growth (revenue 5y +23.6 %/yr in KRW)
Fair value 33,575 KRW · Overvalued
Loss-making · -12.9% net margin (TTM)
Negative free cash flow
Narrow moat 11/100 · thin data
Thin data
Estimate
Watch SK Bioscience Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

335,500 KRW 31,750 KRW Fair Value 33,575 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range 31,750 KRW – 335,500 KRW · fair‑value band 25,181 KRW – 41,968 KRW · the 39,700 KRW price screens above the 33,575 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow SK Bioscience Co in your weekly email

Every Wednesday you see whether SK Bioscience Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally.

Show moreShow less

Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children.

The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States.

SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea. SK bioscience Co.,Ltd. is a subsidiary of SK Chemicals Co.,Ltd.

Stock analysis

SK Bioscience Co Ltd (302440) currently trades at 39,700 KRW, while our estimate is 33,575 KRW, 15% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 25,181 KRW (bear) to 41,968 KRW (bull), the price of 39,700 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

SK Bioscience Co Ltd reported revenue of 651B KRW in FY2025 versus 929B KRW in FY2021, a compound −8.5%/yr. Reported net income was −57.4B KRW in FY2025.

Key figures

Market cap 3.1T KRW (≈ $2.3B) Mid · P/S ratio 4.72 · EPS (TTM) −1,080 KRW · Net margin −12.9% · Return on equity −4.3% · Return on assets (EBIT) 3.6% (5-year average) · Operating margin −10.1% · Revenue (TTM) 659B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 11 out of 100 (low confidence).

What moves the price

The share trades about 29% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −15%, 302440 screens richer than that median.

Fair Value

Bear 25,181 KRW Fair Value 33,575 KRW Bull 41,968 KRW
Price 39,700 KRW · Downside -15.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 45/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 80
Are margins and returns getting better?
Cashflow 20
Do the profits arrive as real cash?
Financial strength 69
Debt, balance sheet and risk of trouble
Investment 46
Does it invest with discipline instead of growing at any price?
Low Volatility 53
How calm the share price moves, does not count
Price momentum 29
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 17
Distance to the 52-week high, does not count
New shares 68
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+143.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.6%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.7% (2020) → −19.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

302440 screens overvalued: fair value 15% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare SK Bioscience Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 45 · Above median
Fair Value upside −15.4% · Above median
Profitability
Return on assets −1.9% · Above median
Net margin (12 months) −12.9% · Below median
Operating margin (12 months) −10.1% · Below median
Growth and dividend
Revenue growth (quarter YoY) −3.8% · Below median
Balance sheet
Debt / equity 0.26× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.74× · Cheaper than median
P/S (12 months) 4.72× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)13 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)87 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 302440
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 302440
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 302440
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 302440
argenx SE ARGX $971.55 $908.40 −7% vs 302440
CSL Limited CSL A$201.68 A$181.40 −10% vs 302440
Moderna, Inc MRNA $250.83 $158.70 −37% vs 302440
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 302440
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 302440
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 302440

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SK Bioscience Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "SK Bioscience Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/302440

Frequently asked questions

Is SK Bioscience Co Ltd (302440) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is 33,575 KRW versus a price of 39,700 KRW, about 15% lower (overvalued).
What is the fair value of 302440?
Our estimate for SK Bioscience Co Ltd is 33,575 KRW (as of Nov 11, 2026), built from audited fundamentals. The current price: 39,700 KRW.
What is the quality score of 302440?
SK Bioscience Co Ltd has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SK Bioscience Co Ltd (302440)?
Our calculated price target is the estimate of 33,575 KRW (as of Nov 11, 2026). Cautious scenario 25,181 KRW, optimistic scenario 41,968 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the SK Bioscience Co Ltd stock forecast for 2026?
Our estimate puts fair value at 33,575 KRW, about 15% lower versus a price of 39,700 KRW (overvalued). Cautious scenario 25,181 KRW, optimistic scenario 41,968 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of SK Bioscience Co Ltd (302440)?
SK Bioscience Co Ltd reported trailing-twelve-month revenue of about 659B KRW (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of SK Bioscience Co Ltd (302440)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SK Bioscience Co Ltd it is 33,575 KRW per share (as of Nov 11, 2026), against a price of 39,700 KRW.
Is SK Bioscience Co Ltd stock overvalued or undervalued in 2026?
As of Nov 11, 2026, 302440 trades above its calculated fair value: price 39,700 KRW, fair value 33,575 KRW, a gap of about −15% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 302440?
No. The price is what the market pays today (39,700 KRW); the fair value is what the company's own numbers justify (33,575 KRW). For SK Bioscience Co Ltd the two are 6,125 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is SK Bioscience Co Ltd worth?
The market values SK Bioscience Co Ltd at about 3.1T KRW (market capitalisation, as of Nov 11, 2026). Per share that is 39,700 KRW; our models calculate a fair value of 33,575 KRW per share.
What do the bullish and bearish scenarios say about 302440?
Our models span a range for SK Bioscience Co Ltd: cautious scenario 25,181 KRW, base 33,575 KRW, optimistic 41,968 KRW per share (as of Nov 11, 2026, price 39,700 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of SK Bioscience Co Ltd (302440)?
Balance-sheet figures for SK Bioscience Co Ltd (as of Nov 11, 2026): return on equity −4.3%, debt of 0.26 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 302440 from its 52-week high?
SK Bioscience Co Ltd trades at 39,700 KRW, about 29% below its 52-week high of 56,000 KRW and 25% above the low of 31,750 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 33,575 KRW is for.
Which stocks are comparable to SK Bioscience Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SK Bioscience Co Ltd stock attractive at the current price?
The data as of Nov 11, 2026: price 39,700 KRW, calculated fair value 33,575 KRW (−15%), Quality Score 45/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. SK Bioscience Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SK Bioscience Co Ltd (302440)?
The closing price on Nov 10, 2026 was 39,700 KRW. Our estimate is 33,575 KRW, about 15% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SK Bioscience Co Ltd right now?
Weak quality (45/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of SK Bioscience Co Ltd

How large is the market capitalisation of SK Bioscience Co Ltd (302440)?
The market capitalisation of SK Bioscience Co Ltd is 3.1T KRW (≈ $2.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SK Bioscience Co Ltd (302440)?
The price-to-sales ratio of SK Bioscience Co Ltd is 4.72 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SK Bioscience Co Ltd (302440)?
Earnings per share at SK Bioscience Co Ltd are −1,080 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of SK Bioscience Co Ltd (302440)?
The net margin of SK Bioscience Co Ltd is −12.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SK Bioscience Co Ltd (302440)?
The return on equity (ROE) of SK Bioscience Co Ltd is −4.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SK Bioscience Co Ltd (302440)?
On an EBIT basis the return on assets of SK Bioscience Co Ltd is 3.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SK Bioscience Co Ltd (302440)?
The operating margin of SK Bioscience Co Ltd is −10.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SK Bioscience Co Ltd (302440)?
Revenue at SK Bioscience Co Ltd is growing −3.8% versus a year earlier (3y avg +12.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at SK Bioscience Co Ltd (302440)?
Earnings per share at SK Bioscience Co Ltd are growing −84.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does SK Bioscience Co Ltd (302440) generate?
The free cash flow of SK Bioscience Co Ltd is −158B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does SK Bioscience Co Ltd (302440) carry?
The net debt of SK Bioscience Co Ltd is 359B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch SK Bioscience Co Ltd in the live analysis

One click puts SK Bioscience Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.